Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 13/20 | 0.39 |
| ▸ | MAG | P20916 | 2/20 | 0.37 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.37 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13029020 | 0.94 | CD22 (0.40) | CD22MAGNANP | |
| SCHEMBL12991357 | 0.83 | NANP (0.44) | CD22MAGNANP | |
| SCHEMBL14366095 | 0.82 | NANP (0.44) | CD22MAGNANP | |
| SCHEMBL15677307 | 0.79 | NANP (0.51) | CD22MAGNANP | |
| SCHEMBL12730475 | 0.79 | NANP (0.44) | CD22MAGNANP | |
| SCHEMBL12341443 | 0.79 | NANP (0.44) | CD22MAGNANP | |
| SCHEMBL14454528 | 0.79 | NANP (0.44) | CD22MAGNANP | |
| SCHEMBL13912421 | 0.78 | NANP (0.41) | CD22MAGNANP | |
| SCHEMBL13402336 | 0.77 | CD22 (0.37) | CD22NANPSIGLEC7 | |
| SCHEMBL22837962 | 0.77 | NANP (0.52) | CD22MAGNANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842661-B2 | Glycopegylated erythropoietin formulations | NOVO NORDISK A/S (DK) | 2010-11-30 | — | — | US | disclosed |
| US-20100210507-A9 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210507-A9 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | CD22 290/4885MAG 265/4885NANP 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.